UK - Oxfam and FairPensions have warned investing in pharmaceutical companies that try to block poor countries' access to affordable drugs might damage reputations and lead to falling returns.
Richard English, trade campaign manager at Oxfam, said pension holders had a right to know how their money was being invested: “By voicing your concerns in this way, you could be helping to secure a more sustainable future for millions of people in the developing world.”
The warning came in a letter to funds and investment institutions targeting companies such as Novartis who are currently challenging Indian patent law. This challenge could see HIV/Aids medicines put out of the developing world’s financial reach.
Oxfam said it wanted investors to understand many developing countries were fighting these challenges. Cases such as Glaxo SmithKline’s attempt at legal action against the South African government in 2001 was withdrawn due to investor pressure.
FairPensions executive director and former JP Morgan investment manager, Alex van de Velden, added: “ Investors need to monitor and manage the environmental and social issues that could damage returns in the medium term, and attempts to restrict access to medicines are a good example of a corporate strategy that could backfire.”
A number of pension schemes have been prompted to lock in gains with a move into bonds after the estimated deficit across FTSE 100 DB pension schemes improved by £36bn, over the 12 months ending 30 June last year, JLT Employment Benefits found.
HM Treasury has agreed in principle to give NEST a £329m contingent liability guarantee in the event of the master trust's wind up or closure.
AMP Capital has set up a dedicated team to help institutional investors, including pension funds, invest in infrastructure through direct equity allocations.